LAES enters the second week of July with bears firmly in control — the stock has shed 11% in a week, borrow costs have nearly quadrupled since late May, and the CEO and CFO have been selling into every modest rally.
The borrow market tells the most urgent story. Lending availability has tightened sharply, falling to 17% — meaning for every six shares already borrowed, only one remains available for new shorts. That is well below the halfway mark that signals a strained lending pool, and it has deteriorated further this week, down roughly 10% from seven days ago. Cost to borrow has climbed from around 13% in late May to nearly 47% today, a more than threefold rise in six weeks. The 30-day change in CTB is up 24%. Short interest itself is running at 10.9% of the free float — elevated but down fractionally on the week, suggesting the shorts already in place are holding rather than adding. ORTEX ranks the short score at 77.3 out of 100, near the highest readings of the past fortnight, and the stock sits in the 1st percentile on short score rank across the universe — as short-side pressure as it gets.
Options positioning adds a different shade to the same picture. The put/call ratio has jumped to 0.030, more than two and a half standard deviations above its 20-day average of 0.024. That sounds small in absolute terms, but the z-score of 2.6 is the highest reading in months and marks a genuine break from the baseline. For a name where puts have historically been an afterthought — the 52-week PCR high is only 0.35 — even a modest shift toward downside protection is notable. Taken together, tight availability, elevated borrow cost, high short interest, and a sudden spike in put demand describe a market that is actively paying to stay bearish.
The insider register reinforces that caution. The CEO and CFO have both sold shares repeatedly since late May, with the pattern stretching from May 29 through June 5 — small lots, but consistent and concurrent. The 90-day net insider figure shows net selling of roughly 369,000 shares, worth around $1.1 million at prevailing prices. None of the individual transactions are enormous in dollar terms, but the cluster of C-suite sales through a falling tape is not the body language of executives betting on a near-term re-rating. A director also sold roughly 96,500 shares on June 16 at $3.07, compared to Tuesday's close of $2.80 — meaning that seller is already underwater on a trade made just three weeks ago.
The Street is thin on coverage. Cantor Fitzgerald initiated with an Overweight rating in December 2025, then cut the target from $7 to $4 in April 2026 — still well above the current price of $2.80, but the direction of travel matters. At a $4 target, the analyst implies roughly 43% upside from here, yet the ongoing stock weakness and borrow pressure suggest the market is not yet buying that thesis. The analyst data here reflects only one active covering firm, so consensus is effectively a single voice. The ORTEX short score rank of 1 and days-to-cover rank of 8 highlight how extreme the bearish positioning looks relative to peers.
Those peers have also had a rough week. Closest correlated names RGTI and ASTI both fell around 15% on the week, while AEHR dropped nearly 30%. The sector-wide pressure means LAES is not suffering in isolation — but its combination of elevated short interest, tightening borrow, and insider selling makes it more structurally exposed than most of its Nasdaq semiconductor neighbours.
The next earnings date is September 10. Between now and then, the key tension is whether the borrow pool tightens toward the 52-week floor of near-zero availability — which briefly occurred earlier this year — or whether the stock finds a level that attracts fresh buyers and allows shorts to cover. At $2.80, with availability already under 20% and CTB running at nearly 47%, any catalyst that forces position unwinds will find the lending market very thin indeed.
See the live data behind this article on ORTEX.
Open LAES on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
